Cargando…

A phase 1, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects

AIM: To assess safety, tolerability, and pharmacokinetics of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adults. METHODS: A phase 1, double‐blind, randomized, placebo‐controlled, single‐ and multiple‐dose study in Japanese and Caucasian subjects. Subjects received lisdexamfetamine...

Descripción completa

Detalles Bibliográficos
Autores principales: Ermer, James, Martin, Patrick, Corcoran, Mary, Matsuo, Yumiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292221/
https://www.ncbi.nlm.nih.gov/pubmed/31765110
http://dx.doi.org/10.1002/npr2.12082
_version_ 1783546065448861696
author Ermer, James
Martin, Patrick
Corcoran, Mary
Matsuo, Yumiko
author_facet Ermer, James
Martin, Patrick
Corcoran, Mary
Matsuo, Yumiko
author_sort Ermer, James
collection PubMed
description AIM: To assess safety, tolerability, and pharmacokinetics of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adults. METHODS: A phase 1, double‐blind, randomized, placebo‐controlled, single‐ and multiple‐dose study in Japanese and Caucasian subjects. Subjects received lisdexamfetamine 20 mg or placebo on Day 1, then lisdexamfetamine 20 mg/d (Days 4‐8), 50 mg/d (Days 9‐13), 70 mg/d (Days 14‐18), or matching placebo. Pharmacokinetic parameters for lisdexamfetamine and d ‐amphetamine were estimated by noncompartmental analysis. RESULTS: Fifteen Japanese and 19 Caucasian subjects were enrolled and randomized. The lisdexamfetamine and d ‐amphetamine plasma concentration‐time curves were similar for both ethnic groups following single and multiple doses. Mean area under the concentration‐time curves for d ‐amphetamine were higher (by 11%‐15%) in Japanese than Caucasian subjects following multiple dosing of lisdexamfetamine. Mean bodyweight was 17% lower in Japanese than Caucasian subjects. Weight‐corrected means for oral clearance were similar in both ethnic groups, with no unexpected accumulation of d ‐amphetamine. Lisdexamfetamine was generally well tolerated by both ethnic groups, with no serious adverse events reported. The 10/12 Japanese and 11/16 Caucasian subjects who received lisdexamfetamine completed the study; two Japanese and three Caucasian subjects discontinued due to adverse events. Most adverse events were of mild severity. CONCLUSION: Pharmacokinetics were generally similar for Japanese and Caucasian subjects; the minor differences observed were likely due to bodyweight differences in the two ethnic groups. Lisdexamfetamine was generally well tolerated. Adverse events were consistent with the established safety profile of lisdexamfetamine and were similar in both ethnic groups.
format Online
Article
Text
id pubmed-7292221
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-72922212020-12-08 A phase 1, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects Ermer, James Martin, Patrick Corcoran, Mary Matsuo, Yumiko Neuropsychopharmacol Rep Original Articles AIM: To assess safety, tolerability, and pharmacokinetics of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adults. METHODS: A phase 1, double‐blind, randomized, placebo‐controlled, single‐ and multiple‐dose study in Japanese and Caucasian subjects. Subjects received lisdexamfetamine 20 mg or placebo on Day 1, then lisdexamfetamine 20 mg/d (Days 4‐8), 50 mg/d (Days 9‐13), 70 mg/d (Days 14‐18), or matching placebo. Pharmacokinetic parameters for lisdexamfetamine and d ‐amphetamine were estimated by noncompartmental analysis. RESULTS: Fifteen Japanese and 19 Caucasian subjects were enrolled and randomized. The lisdexamfetamine and d ‐amphetamine plasma concentration‐time curves were similar for both ethnic groups following single and multiple doses. Mean area under the concentration‐time curves for d ‐amphetamine were higher (by 11%‐15%) in Japanese than Caucasian subjects following multiple dosing of lisdexamfetamine. Mean bodyweight was 17% lower in Japanese than Caucasian subjects. Weight‐corrected means for oral clearance were similar in both ethnic groups, with no unexpected accumulation of d ‐amphetamine. Lisdexamfetamine was generally well tolerated by both ethnic groups, with no serious adverse events reported. The 10/12 Japanese and 11/16 Caucasian subjects who received lisdexamfetamine completed the study; two Japanese and three Caucasian subjects discontinued due to adverse events. Most adverse events were of mild severity. CONCLUSION: Pharmacokinetics were generally similar for Japanese and Caucasian subjects; the minor differences observed were likely due to bodyweight differences in the two ethnic groups. Lisdexamfetamine was generally well tolerated. Adverse events were consistent with the established safety profile of lisdexamfetamine and were similar in both ethnic groups. John Wiley and Sons Inc. 2019-11-25 /pmc/articles/PMC7292221/ /pubmed/31765110 http://dx.doi.org/10.1002/npr2.12082 Text en © 2019 Takeda. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japan Society of Neuropsychopharmacology. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Ermer, James
Martin, Patrick
Corcoran, Mary
Matsuo, Yumiko
A phase 1, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects
title A phase 1, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects
title_full A phase 1, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects
title_fullStr A phase 1, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects
title_full_unstemmed A phase 1, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects
title_short A phase 1, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects
title_sort phase 1, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in japanese and caucasian healthy adult subjects
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292221/
https://www.ncbi.nlm.nih.gov/pubmed/31765110
http://dx.doi.org/10.1002/npr2.12082
work_keys_str_mv AT ermerjames aphase1randomizeddoubleblindplacebocontrolledstudytoevaluatethesafetytolerabilityandpharmacokineticsofsingleandmultipledosesoflisdexamfetaminedimesylateinjapaneseandcaucasianhealthyadultsubjects
AT martinpatrick aphase1randomizeddoubleblindplacebocontrolledstudytoevaluatethesafetytolerabilityandpharmacokineticsofsingleandmultipledosesoflisdexamfetaminedimesylateinjapaneseandcaucasianhealthyadultsubjects
AT corcoranmary aphase1randomizeddoubleblindplacebocontrolledstudytoevaluatethesafetytolerabilityandpharmacokineticsofsingleandmultipledosesoflisdexamfetaminedimesylateinjapaneseandcaucasianhealthyadultsubjects
AT matsuoyumiko aphase1randomizeddoubleblindplacebocontrolledstudytoevaluatethesafetytolerabilityandpharmacokineticsofsingleandmultipledosesoflisdexamfetaminedimesylateinjapaneseandcaucasianhealthyadultsubjects
AT ermerjames phase1randomizeddoubleblindplacebocontrolledstudytoevaluatethesafetytolerabilityandpharmacokineticsofsingleandmultipledosesoflisdexamfetaminedimesylateinjapaneseandcaucasianhealthyadultsubjects
AT martinpatrick phase1randomizeddoubleblindplacebocontrolledstudytoevaluatethesafetytolerabilityandpharmacokineticsofsingleandmultipledosesoflisdexamfetaminedimesylateinjapaneseandcaucasianhealthyadultsubjects
AT corcoranmary phase1randomizeddoubleblindplacebocontrolledstudytoevaluatethesafetytolerabilityandpharmacokineticsofsingleandmultipledosesoflisdexamfetaminedimesylateinjapaneseandcaucasianhealthyadultsubjects
AT matsuoyumiko phase1randomizeddoubleblindplacebocontrolledstudytoevaluatethesafetytolerabilityandpharmacokineticsofsingleandmultipledosesoflisdexamfetaminedimesylateinjapaneseandcaucasianhealthyadultsubjects